A new drug to treat Type 2 diabetes is now available in the UK.
Januvia (Sitagliptin) is an add-on treatment for people with Type 2 diabetes. It is a DPP-4 inhibitor which works by increasing the levels of hormones in the body called incretins. These hormones are released throughout the day and levels are increased at meal times. They work in the body in two ways:
- Produce more insulin only when needed.
- Reduce the amount of glucose being produced by the liver when it is not needed.
“Diabetes UK welcomes any advances that help improve quality of life for people with diabetes," said Simon O’Neill, Director of Care, Information and Advocacy Services at Diabetes UK.
“In some cases, Type 2 diabetes can be managed through lifestyle adjustments such as eating a healthy, balanced diet and taking regular physical activity. When managing the condition in this way is not possible, Diabetes UK recognises that a wide choice of treatment options, including Januvia (sitagliptin) in combination with metformin or glitazone tablets, can help.
“People with diabetes should have as wide a choice as possible of effective treatments for their condition. Good blood glucose control is essential for people with diabetes to improve wellbeing and protect against long-term damage to the eyes, kidneys, nerves, heart and major arteries.”
Januvia (Sitagliptin) is taken in tablet form once a day with or without food. It is an add-on treatment suitable for use with either Metformin or a Glitazone. It is currently not licensed as mono-therapy, triple-therapy or as an add-on medicine with insulin.